未找到相关数据
Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK plus NSCLC.
被引：16
作者：
Camidge, D. Ross
Peters, Solange
Mok, Tony
Gadgeel, Shirish M.
Cheema, Parneet K.
Pavlakis, Nick
De Marinis, Filippo
Stroyakovskiy, Daniil L.
Cho, Byoung Chul
Zhang, Li
Moro-Sibilot, Denis
Zeaiter, Ali Hassan
Mitry, Emmanuel
Balas, Bogdana
Mueller, Barbara
Shaw, Alice
机构：
[1] Univ Colorado, Aurora, CO USA
[2] Ctr Hosp Univ Vaudois CHUV, Lausanne, Switzerland
[3] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Northern Canc Inst, Sydney, NSW, Australia
[7] European Inst Oncol, Milan, Italy
[8] Moscow City Oncol Hosp 62, Moscow Dept Hlth, Moscow, Russia
[9] Severence Hosp, Seoul, South Korea
[10] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[11] Grenoble Univ Hosp, Grenoble, France
[12] F Hoffmann La Roche Ltd, Basel, Switzerland
[13] Massachusetts Gen Hosp, Boston, MA 02114 USA
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9043
引用
收藏
页数：2
相关论文